Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Primary objective: To evaluate the efficacy of two different dosing schedules of MS-275 in
subjects with metastatic melanoma Secondary objectives: To evaluate the safety and to assess
the pharmacokinetic profile of MS-275 in subjects with metastatic melanoma